Test Price
800 AEDโ Home Collection Available
Mycobacterium tuberculosis First- & Second-Line Drug Resistance Profile (Line Probe Assay) in UAE | 800 AED
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
- DHA Licensed: Facility License No. 1143 | Dubai Healthcare City.
Test Overview & Methodology
The Mycobacterium tuberculosis First- and Second-Line Drug Resistance Profile detects genetic mutations conferring resistance to isoniazid, rifampicin, fluoroquinolones, and injectable agents using PCR and Line Probe Assay technology, enabling rapid initiation of appropriate MDR/XDR-TB therapy. This molecular assay simultaneously interrogates key resistance genes including rpoB, katG, inhA, gyrA, and rrs, providing comprehensive resistance profiling within days instead of weeks required by conventional culture methods.
| Feature | Our Advanced Molecular Test (PCR + LPA) | Conventional Culture DST |
|---|---|---|
| Methodology | Polymerase Chain Reaction (PCR) & Line Probe Assay (HAIN GenoType MTBDRplus/sl) | Phenotypic culture on LJ/MGIT; drug susceptibility testing weeks later |
| Turnaround Time | Sample by 11 am Saturday โ Report Friday (5 days) | 4โ8 weeks |
| Sensitivity for Key Mutations | >95% for common resistance markers | ~90% but requires viable culture |
| Clinical Actionability | Rapid identification of MDR/XDR-TB, enabling immediate appropriate therapy | Delayed; patient may continue ineffective treatment risking amplification of resistance |
Physician Insight & Safety Protocols
โThe line probe assay for first- and second-line drug resistance profiling provides a critical time advantage in managing drug-resistant tuberculosis. While this molecular result is highly reliable for guiding initial therapy, it must always be correlated with clinical presentation, chest imaging, and where possible, phenotypic drug susceptibility testing to detect emerging or mixed resistance patterns. Treatment decisions should involve consultation with an infectious disease specialist or pulmonologist experienced in MDR-TB management.โ
โ Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Clinical Advisory
โ Important Clinical Guidance
Do not discontinue, alter, or interrupt prescribed anti-tuberculosis medication without explicit consultation with your treating physician. Abrupt cessation of therapy can lead to disease relapse and amplification of drug resistance, compromising both individual and public health outcomes.
Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Inability to produce sputum despite induction, uncontrolled hemoptysis, known allergy to local anesthetics (for bronchoscopic lavage), severe respiratory distress at rest, or active hemoptysis exceeding 50 mL within the preceding 24 hours.
- Emergency Red Flags โ Seek immediate medical attention if you experience: Hemoptysis > 50 mL, new onset severe breathlessness at rest, fever > 39ยฐC with rigors unresponsive to antipyretics, chest pain unrelieved by analgesia, or confusion/altered consciousness.
Patient FAQ & Clinical Guidance
1. Why do I need a first- and second-line drug resistance profile instead of a standard TB test?
This molecular assay simultaneously detects resistance mutations to isoniazid, rifampicin, fluoroquinolones, and injectable agents within days, not weeks. While a standard TB test only confirms the presence of Mycobacterium tuberculosis, this comprehensive profile identifies the specific resistance pattern, allowing your pulmonologist to prescribe an effective, individualized regimen immediately. This rapid turnaround avoids the 4- to 8-week delay of culture-based drug susceptibility testing, which is critical for preventing disease progression and reducing transmission in the community.
2. Is the sputum collection painful, and can it be done at home?
Sputum collection is a minimally invasive procedure involving deep coughing to produce respiratory secretions. Our VIP Mobile Phlebotomy team performs collection at your home following strict cold-chain transport protocols from 8 AM to 11 PM daily. For patients unable to produce sputum naturally, sputum induction using nebulized hypertonic saline can be arranged under medical supervision. All specimens are transported in temperature-controlled containers directly to our ISO-accredited laboratory, ensuring specimen integrity comparable to hospital-based collection.
3. How reliable is the result compared to traditional culture testing?
The line probe assay demonstrates over 95% sensitivity and 99% specificity for common resistance mutations when validated against the gold-standard phenotypic drug susceptibility testing (DST). The World Health Organization endorses LPA as a frontline diagnostic tool for MDR-TB detection. However, because LPA detects only known genetic mutations, rare or novel resistance mechanisms may be missed. Therefore, correlation with clinical response and follow-up culture-based DST is recommended for comprehensive management, particularly in patients with prior treatment failure or exposure to second-line drugs.
UAE Regulatory & Data Privacy Adherence
Data Protection & Health Information Governance: This laboratory service fully complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All patient data is encrypted in transit and at rest, accessed only by authorized clinical personnel under strict role-based access controls.
Clinical Safety & Patient Consent: Clinical testing procedures and patient consent protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring that all molecular diagnostics are performed with informed patient consent and result in actionable clinical guidance.
Laboratory Accreditation: ISO 9001:2015 Certified (INT/EGQ/2509DA/3139) | DHA Facility License No. 1143 | All results must be interpreted by a licensed physician. This page does not constitute medical advice.
Clinical & Logistical Metadata
| Test Name | Mycobacterium tuberculosis First- & Second-Line Drug Resistance Profile (Line Probe Assay) |
| Price (AED) | 800 AED |
| Turnaround Time | Sample by 11 am Saturday โ Report Friday (5 business days) |
| Sample Type / Matrix | Sputum, Bronchoalveolar Lavage (BAL), or Respiratory Specimen |
| Methodology Used | Multiplex PCR with Reverse Hybridization Line Probe Assay (HAIN GenoType MTBDRplus/sl) |
| ICD-10-CM Code | A15.0 (Tuberculosis of lung), A15.4 (Tuberculosis of intrathoracic lymph nodes) |
| LOINC Code | 76968-1 (Mycobacterium tuberculosis drug resistance panel by Molecular method) |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians